An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment

Trial Profile

An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2012

At a glance

  • Drugs PSI 938; Sofosbuvir
  • Indications Hepatitis C
  • Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2012 Actual patients number is 24 as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Actual initiation date changed from May 2011 to Jul 2011, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top